Have we pushed the needle for treatment of Type 1 diabetes?
| Autor: | Kevan C. Herold, Ana Luisa Perdigoto, Jinxiu Rui, Nida Naushad |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Future studies Immunology Disease Bioinformatics Autoantigens Article 03 medical and health sciences 0302 clinical medicine Immune system Immunologics Antigen specific Insulin-Secreting Cells Immune Tolerance medicine Animals Humans Immunology and Allergy Molecular Targeted Therapy 030212 general & internal medicine Adverse effect Biological Products Type 1 diabetes business.industry medicine.disease Disease Models Animal Diabetes Mellitus Type 1 030104 developmental biology Immunotherapy business |
| Zdroj: | Current Opinion in Immunology. 49:44-50 |
| ISSN: | 0952-7915 |
| DOI: | 10.1016/j.coi.2017.09.004 |
| Popis: | Studies with immunologics have shown that the natural history of Type 1 diabetes can be modified. These studies have targeted key mediators of the disease and recent analyses, together with studies in preclinical models have identified mechanisms that may be involved in the clinical effects. Several issues remain including specificity of the interventions, adverse effects of the treatments, and duration of their effects. Future studies are likely to include more specific approaches with agents such as cell therapies with selected immune regulatory subsets, antigen specific therapies, and combinations of agents with complementary mechanisms of activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect